Merck & Co., Inc. Price Target Raised to $161.00 by Leerink Partners

Merck & Co., Inc.'s (NYSE:MRK) price target was raised to $161.00 by Leerink Partners, marking a significant increase from its previous estimate of $127.00.

This new target points to a potential upside of 9.05% from the company's current price. The brokerage currently maintains an 'outperform' rating on the stock.

Leerink Partners is not alone in revising its estimates for Merck & Co., Inc. Several other research analysts have also commented on the company, with Bank of America boosting its target to $141.00 and Cantor Fitzgerald reaffirming a 'neutral' rating at $120.00.

The upgrade reinforces confidence in Merck's earnings outlook and pipeline prospects. The company has gained about 85% over the past year and is trading close to its 52-week high, driven by Keytruda's continued growth as well as newer products and pipeline programs.